C4 Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
C4 Therapeutics, Inc. (CCCC) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.45M, a 12.83% decline year-over-year.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.44M, a 12.61% decline year-over-year.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.43M, a 12.39% decline year-over-year.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.69M, a 4.58% increase year-over-year.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $6.43M, a 0.20% increase from fiscal 2024.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $6.42M, a 4.25% increase from fiscal 2023.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.16M, a 4.46% increase from fiscal 2022.
- C4 Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.90M, a 316.68% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.90M 10-Q · filed 2026-08-11 | $4.32M derived: sum of 3 quarters · filed 2026-08-11 | $6.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-12 | $2.87M derived: sum of 2 quarters · filed 2026-05-12 | $4.56M derived: sum of 3 quarters · filed 2026-05-12 | $6.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.12M derived: sum of 2 quarters · filed 2026-02-26 | $4.79M derived: sum of 3 quarters · filed 2026-08-11 | $6.43M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.36M derived: sum of 2 quarters · filed 2026-08-11 | $5.00M 10-Q · filed 2025-11-06 | $6.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.32M 10-Q · filed 2026-08-11 | $4.95M derived: sum of 3 quarters · filed 2026-08-11 | $6.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.65M 10-Q · filed 2026-05-12 | $3.28M derived: sum of 2 quarters · filed 2026-05-12 | $4.89M derived: sum of 3 quarters · filed 2026-05-12 | $6.49M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.25M derived: sum of 2 quarters · filed 2026-02-26 | $4.84M derived: sum of 3 quarters · filed 2026-02-26 | $6.42M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.21M derived: sum of 2 quarters · filed 2025-11-06 | $4.79M 10-Q · filed 2025-11-06 | $6.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.18M 10-Q · filed 2025-08-07 | $4.74M derived: sum of 3 quarters · filed 2025-08-07 | $6.29M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.58M 10-Q · filed 2025-05-07 | $3.14M derived: sum of 2 quarters · filed 2025-05-07 | $4.69M derived: sum of 3 quarters · filed 2025-05-07 | $6.22M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.11M derived: sum of 2 quarters · filed 2025-02-27 | $4.64M derived: sum of 3 quarters · filed 2025-02-27 | $6.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $3.08M derived: sum of 2 quarters · filed 2024-10-31 | $4.60M 10-Q · filed 2024-10-31 | $6.10M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.05M 10-Q · filed 2024-08-01 | $4.55M derived: sum of 3 quarters · filed 2024-08-01 | $6.05M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $1.52M 10-Q · filed 2024-05-08 | $3.02M derived: sum of 2 quarters · filed 2024-05-08 | $4.52M derived: sum of 3 quarters · filed 2024-05-08 | $6.23M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.01M derived: sum of 2 quarters · filed 2024-02-22 | $4.71M derived: sum of 3 quarters · filed 2024-02-22 | $5.90M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $3.21M derived: sum of 2 quarters · filed 2023-11-01 | $4.39M 10-Q · filed 2023-11-01 | $4.83M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.89M 10-Q · filed 2023-08-08 | $3.33M derived: sum of 3 quarters · filed 2023-08-08 | $3.66M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.18M 10-Q · filed 2023-05-04 | $1.62M derived: sum of 2 quarters · filed 2023-05-04 | $1.95M derived: sum of 3 quarters · filed 2023-05-04 | $2.28M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $768.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.09M derived: sum of 3 quarters · filed 2023-02-23 | $1.42M 10-K · filed 2023-02-23 |
| 2021-09-30 | $333.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $660.00K derived: sum of 2 quarters · filed 2022-11-03 | $980.00K 10-Q · filed 2022-11-03 | $1.29M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $327.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $647.00K 10-Q · filed 2022-08-04 | $961.00K derived: sum of 3 quarters · filed 2022-08-04 | $1.27M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $320.00K 10-Q · filed 2022-05-05 | $634.00K derived: sum of 2 quarters · filed 2022-05-05 | $944.00K derived: sum of 3 quarters · filed 2022-05-05 | $1.25M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $624.00K derived: sum of 2 quarters · filed 2022-02-24 | $926.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.22M 10-K · filed 2022-02-24 |
| 2020-09-30 | $310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $612.00K derived: sum of 2 quarters · filed 2021-11-10 | $910.00K 10-Q · filed 2021-11-10 | $1.20M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $600.00K 10-Q · filed 2021-08-11 | $894.00K derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $298.00K 10-Q · filed 2021-05-13 | $592.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.14M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $850.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |